Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rujiexiao
- Development stage
- Phase 2
- Lead developer
- Tailong
- Administration
- Oral
01
Overview
Rujiexiao is a Traditional Chinese Medicine (TCM) preparation developed by Henan Tailong Pharmaceutical Co., Ltd., primarily in the form of granules. It is designed to treat breast hyperplasia and breast nodules, specifically targeting the Liver Qi Stagnation and Phlegm Coagulation pattern in TCM theory. The formulation works by soothing the liver, regulating Qi circulation, and resolving phlegm to alleviate breast pain and reduce the size of nodules. It has undergone Phase II clinical evaluation in China to assess its efficacy and safety in patients with these conditions.
- Brand names
- Rujiexiao Granules
- Other names
- 乳解消颗粒
02
Targets
OPRT (Orotidine 5'-phosphate decarboxylase)SYK (Spleen Tyrosine Kinase)
Beyond the preview
Go deeper on Rujiexiao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rujiexiao.